Literature DB >> 27311870

TROP-2 immunohistochemistry: a highly accurate method in the differential diagnosis of papillary thyroid carcinoma.

Andrey Bychkov1, Pichet Sampatanukul2, Shanop Shuangshoti3, Somboon Keelawat2.   

Abstract

We aimed to evaluate the diagnostic utility of the novel immunohistochemical marker TROP-2 on thyroid specimens (226 tumours and 207 controls). Whole slide immunohistochemistry was performed and scored by automated digital image analysis. Non-neoplastic thyroid, follicular adenomas, follicular carcinomas, and medullary carcinomas were negative for TROP-2 immunostaining. The majority of papillary thyroid carcinoma (PTC) specimens (94/114, 82.5%) were positive for TROP-2; however, the pattern of staining differed significantly between the histopathological variants. All papillary microcarcinomas (mPTC), PTC classic variant (PTC cv), and tall cell variant (PTC tcv) were TROP-2 positive, with mainly diffuse staining. In contrast, less than half of the PTC follicular variant specimens were positive for TROP-2, with only focal immunoreactivity. TROP-2 could identify PTC cv with 98.1% sensitivity and 97.5% specificity. ROC curve analysis found that the presence of >10% of TROP-2 positive cells in a tumour supported a diagnosis of PTC. The study of intratumoural heterogeneity showed that low-volume cytological samples of PTC cv could be adequately assessed by TROP-2 immunostaining. The TROP-2 H-score (intensity multiplied by proportion) was significantly associated with PTC variant and capsular invasion in encapsulated PTC follicular variant (p<0.001). None of the baseline (age, gender) and clinical (tumour size, nodal disease, stage) parameters were correlated with TROP-2 expression. In conclusion, TROP-2 membranous staining is a very sensitive and specific marker for PTC cv, PTC tcv, and mPTC, with high overall specificity for PTC.
Copyright © 2016 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  TROP-2; automated image analysis; differential diagnosis; immunohistochemistry; papillary thyroid carcinoma; thyroid

Mesh:

Substances:

Year:  2016        PMID: 27311870     DOI: 10.1016/j.pathol.2016.04.002

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  9 in total

1.  Epstein-Barr virus and thyroid cancer: the controversy remains.

Authors:  A Bychkov; S Keelawat
Journal:  J Endocrinol Invest       Date:  2017-05-30       Impact factor: 4.256

2.  The diagnostic value of TROP-2, SLP-2 and CD56 expression in papillary thyroid carcinoma.

Authors:  Xueyang Yang; Yifang Hu; He Shi; Chengzhou Zhang; Zhixiao Wang; Xiaoyun Liu; Huanhuan Chen; Lijuan Zhang; Dai Cui
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-06-27       Impact factor: 2.503

3.  Epithelial hyperplasia is responsible for the compensatory enlargement of remaining thyroid lobe after thyroidectomy.

Authors:  Andrey Bychkov
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-02-26       Impact factor: 2.503

4.  An affordable immunohistochemical approach to estimate the prevalence of BRAFV600E in large cohort studies-establishing the baseline rate of BRAF mutation in an institutional series of papillary thyroid carcinoma from Thailand.

Authors:  Sonam Choden; Somboon Keelawat; Chan Kwon Jung; Andrey Bychkov
Journal:  Gland Surg       Date:  2020-10

Review 5.  Current Status of Thyroid Fine-Needle Aspiration Practice in Thailand.

Authors:  Somboon Keelawat; Samreung Rangdaeng; Supinda Koonmee; Tikamporn Jitpasutham; Andrey Bychkov
Journal:  J Pathol Transl Med       Date:  2017-11-15

6.  PSMA expression by microvasculature of thyroid tumors - Potential implications for PSMA theranostics.

Authors:  Andrey Bychkov; Usanee Vutrapongwatana; Supatporn Tepmongkol; Somboon Keelawat
Journal:  Sci Rep       Date:  2017-07-12       Impact factor: 4.379

Review 7.  Trop2: Jack of All Trades, Master of None.

Authors:  Sára Lenárt; Peter Lenárt; Jan Šmarda; Ján Remšík; Karel Souček; Petr Beneš
Journal:  Cancers (Basel)       Date:  2020-11-11       Impact factor: 6.639

8.  Evaluation of Diagnostic Utility of Immunohistochemistry Markers of TROP-2 and HBME-1 in the Diagnosis of Thyroid Carcinoma.

Authors:  Nooshin Zargari; Maral Mokhtari
Journal:  Eur Thyroid J       Date:  2018-11-22

9.  HBME-1 expression in differentiated thyroid carcinoma and its correlation with the ultrasonic manifestation of thyroid.

Authors:  Jiwei Qiao; Chunyu Li; Yuying Zhang; Shuangyan Wang; Shan Gao
Journal:  Oncol Lett       Date:  2017-09-15       Impact factor: 2.967

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.